Anaerostipes caccae Compositions for Treating Allergic and Autoimmune Diseases
Summary
USPTO granted Patent US12589122B2 to the University of Chicago on March 31, 2026, covering compositions and methods for treating infectious, autoimmune, allergic diseases, and food allergies using the bacterium Anaerostipes caccae. The patent includes methods for reducing allergic responses and preventing anaphylactic responses, with claims extending to compositions comprising the bacterium with prebiotics.
What changed
USPTO granted Patent US12589122B2 to the University of Chicago covering methods and compositions for treating infectious, autoimmune, allergic, and food allergy conditions using Anaerostipes caccae bacterium. The patent includes 13 claims directed to therapeutic compositions and methods comprising administering the bacterium alone or with prebiotics to subjects for treating anaphylactic responses, autoimmune conditions, and reducing allergic responses to allergens.
This patent grant is informational and does not impose compliance obligations. Biopharmaceutical companies developing microbiome-based therapeutics should review this patent to assess potential freedom-to-operate implications for similar gut bacteria-based therapies. No immediate action is required; entities should consult patent counsel if their therapeutic programs overlap with the claimed subject matter.
Archived snapshot
Mar 31, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
Methods and compositions for treating infectious, autoimmune, and allergic disease
Grant US12589122B2 Kind: B2 Mar 31, 2026
Assignee
The University of Chicago
Inventors
Cathryn R. Nagler, Riyue Bao, Dionysios Antonopoulos, John W. Colson, Lauren Anders Hesser
Abstract
Provided herein are methods and compositions for treating food allergies, infections, autoimmune conditions, and other allergic conditions. Also provided are methods for treating an infectious, autoimmune, or allergic disease in a subject comprising administering a composition comprising bacterium Anaerostipes caccae to the subject. Further aspects relate to a method for treating a food allergy or for reducing an allergic response to an allergen or for treating or preventing an anaphylactic response in a subject comprising administering a composition comprising bacterium Anaerostipes caccae and a prebiotic to the subject.
CPC Classifications
A61K 35/741 A23L 33/135 A23L 33/21 A61P 37/02 A61P 17/00 A61P 37/08
Filing Date
2019-11-05
Application No.
17309185
Claims
13
Related changes
Get daily alerts for USPTO Patent Grants - Therapeutics (A61P)
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from USPTO.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when USPTO Patent Grants - Therapeutics (A61P) publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.